Q32 Bio Inc.
NASDAQ:QTTBBiotechnology
-$0.22 today
- Market cap
- $253.75M
- Beta
- -0.23
- P/E (TTM)
- 5.4
- EPS (TTM)
- $2.36
Volume 0.31M
Average 0.74M
Returns on capital
Q32 Bio Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
71.0%
avg -109.3%
ROIC
29.5%
avg -61.6%
ROA
48.3%
avg -41.4%
Analysis
ROE is currently the strongest return metric at 71.0% versus its period average of -109.3%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Jodie Pope Morrison | Chief Executive Officer & Director | USD 1M | 50 | 340.04K | 2.66% |
Lee H. Kalowski | Chief Financial Officer & President | USD 792.77K | 45 | — | — |
Shelia Violette | Co-founder, Chief Scientific Officer & President of Research | USD 641.88K | 65 | — | — |
José Trevejo | Chief Medical Officer | USD 627.92K | 54 | — | — |
Elham Hershberger | Chief Development Officer | — | 58 | — | — |
David Appugliese | Senior Vice President & Head of People | — | — | — | — |
Maria Marzilli | Chief Business Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 6, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$30.00M
Sells
11
$505,079.50
Net Transaction Value
+$29.49M
Net buying
Most Active
Morrison Jodie Pope
4 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 6, 26Oct 6, 2026 | Morrison Jodie Pope Direct | Sell | $26.8K$26,798.08 |
| Oct 6, 26Oct 6, 2026 | Kalowski Lee Direct | Sell | $10.8K$10,824.06 |
| Oct 6, 26Oct 6, 2026 | Violette Shelia M. Direct | Sell | $7.6K$7,629.16 |
| Aug 25, 26Aug 25, 2026 | Kalowski Lee Direct | Sell | $65.8K$65,776.32 |
| Aug 25, 26Aug 25, 2026 | Violette Shelia M. Direct | Sell | $46.3K$46,334.88 |
| Aug 25, 26Aug 25, 2026 | Morrison Jodie Pope Direct | Sell | $163K$163,033.20 |
| May 28, 26May 28, 2026 | Xu Diyong Indirect | Buy | $10M$10,000,000.00 |
| May 28, 26May 28, 2026 | Xu Diyong Indirect | Buy | $5M$5,000,000.00 |
| May 28, 26May 28, 2026 | ORBIMED ADVISORS LLC Indirect | Buy | $10M$10,000,000.00 |
| May 28, 26May 28, 2026 | ORBIMED ADVISORS LLC Indirect | Buy | $5M$5,000,000.00 |
1–10 of 15
Summary
Insiders reported 4 buys worth $30.00M and 11 sells worth $505,079.50 over the last 12 months. That adds up to net buying of $29.49M. Morrison Jodie Pope was the most active insider with 4 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | -40.7% (5yr)2 analysts |
| Revenue | N/A | N/A | +100.7% | +23.9% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | -40.7% (5yr)2 analysts |
| EBIT | N/A | N/A | N/A | -27.0% (5yr)2 analysts |
Analysis
Recent growth has been strongest in Revenue at +100.7% over three years. Forward estimates point to Revenue at +23.9% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Q32 Bio Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about QTTB's management, answered from reported figures.
Who manages QTTB?
Q32 Bio Inc. (QTTB) lists 7 active executives. The top listed executive is Shelia Violette, Co-founder, Chief Scientific Officer & President of Research.
Are QTTB insiders buying or selling?
Recent insider activity shows net buying of $34.02M.
Continue the stock analysis
Jump to another research area for this company.